A scientist checks the position of a tray in a pharmaceutical manufacturing facility at Jiangsu Hengrui (Wang Jianmin/Costfoto/Future Publishing via Getty Images)
China’s rise splits US biotech investors: Cash in, or counter?
China’s ascent in drug development has kicked off debate among American investors over how to respond.
Chinese companies are now competitive in some of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
